Watson Pharma (WPI) Receives FDA Approval for Generic Pulmicort RESPULES (AZN)

Article Stock Quotes (2) Comments (0)

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's (NYSE: AZN) Pulmicort RESPULES. Watson is currently involved in patent litigation with AstraZeneca concerning this product. Watson plans to launch the product in 2012 subject to obtaining a favorable outcome on an anticipated motion for a preliminary injunction in the pending litigation.

For the twelve months ending May 31, 2012, Pulmicort RESPULES® had total U.S. sales of approximately $1.1 billion according to IMS Health data. Pulmicort RESPULES® is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
• Men's Wearhouse (MW) Terminates George Zimmer; Postpones Annual Meeting
• Final Conversion Ratio Offered by Pfizer (PFE) for Zoetis (ZTS) Shares is 0.9898

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?